Metsera (NASDAQ:MTSR) Stock Rating Upgraded by Wall Street Zen

Key Points

• Metsera was upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, reflecting a more positive outlook on its stock.
• Other analysts, including Guggenheim and Bank of America, have also upgraded their ratings and price targets for Metsera, with a consensus price target now at $63.50.
• The company, a clinical stage biopharmaceutical firm, has seen significant institutional trading activity, with major firms purchasing large stakes in the first quarter.

Metsera (NASDAQ:MTSR - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Monday.

Other equities research analysts have also issued reports about the company. Leerink Partnrs upgraded Metsera to a "strong-buy" rating in a report on Tuesday, September 9th. Guggenheim upped their price target on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Bank of America upped their price target on Metsera from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, August 28th. Leerink Partners began coverage on Metsera in a report on Tuesday, September 9th. They set an "outperform" rating and a $77.00 price target for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Metsera in a report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $63.50.

Metsera Stock Performance

MTSR opened at $35.67 on Monday. The business has a 50 day moving average price of $35.49 and a 200 day moving average price of $28.91. Metsera has a twelve month low of $12.30 and a twelve month high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Institutional Trading of Metsera

A number of institutional investors and hedge funds have recently modified their holdings of the company. Alphabet Inc. bought a new stake in shares of Metsera during the first quarter valued at approximately $135,059,000. T. Rowe Price Investment Management Inc. bought a new stake in shares of Metsera during the first quarter valued at approximately $78,748,000. Wellington Management Group LLP bought a new stake in shares of Metsera during the first quarter valued at approximately $65,382,000. Alpha Wave Global LP bought a new stake in shares of Metsera during the first quarter valued at approximately $64,894,000. Finally, Price T Rowe Associates Inc. MD bought a new stake in Metsera in the first quarter valued at $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.